GALT

Galectin Therapeutics Inc

• Benzinga·17h ago

  12 Health Care Stocks Moving In Tuesday's After-Market Session

• Reuters·03/31 21:31

  Galectin net loss narrows 34.4% to $31M in FY25

• TipRanks·03/31 20:17

  Galectin Therapeutics files $200M mixed securities shelf

• Reuters·03/31 20:12

  GALECTIN THERAPEUTICS INC - MAY OFFER UP TO $32.5 MLN COMMON STOCK UNDER ATM AGREEMENT WITH H.C. WAINWRIGHT - SEC FILING

• TipRanks·03/31 15:40

  Analysts Have Conflicting Sentiments on These Healthcare Companies: Terns Pharmaceuticals (TERN), Sangamo Therapeutics (SGMO) and Galectin Therapeutics (GALT)

• Benzinga·03/31 14:19

  Galectin Therapeutics Q4 EPS $(0.08) Beats $(0.11) Estimate

• Reuters·03/31 12:09

  Liver drug developer Galectin Therapeutics' 2025 net loss narrows on reduced R&D costs

• Dow Jones·03/31 12:03

  *Galectin Therapeutics 2025 Research and Development Expenses $14.3M >GALT

• Reuters·03/31 12:00

  GALECTIN THERAPEUTICS FY EPS USD -0.48

• Reuters·03/31 12:00

  GALECTIN THERAPEUTICS INC - FY2025 NET LOSS APPLICABLE TO COMMON STOCKHOLDERS WAS $31.0 MLN, OR ($0.48) PER SHARE

• Reuters·03/31 12:00

  GALECTIN THERAPEUTICS REPORTS 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

• Dow Jones·03/31 12:00

  Press Release: Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update

• Dow Jones·03/31 12:00

  Press Release: Galectin Therapeutics Reports 2025 -2-

• Reuters·03/17 13:46

  Galectin Therapeutics Director Henry Brem Files Initial Beneficial Ownership Statement

• TipRanks·03/17 12:43

  Galectin Therapeutics Adds Neurosurgeon Henry Brem to Board